Quick Answer
Cellectar Biosciences, Inc. reported Operating Income of -$22.98 million for fiscal year 2025.
Cellectar Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$22.98M | +55.6% |
| 2024 | -$51.78M | -32.9% |
| 2023 | -$38.96M | -35.2% |
| 2022 | -$28.81M | -19.4% |
| 2021 | -$24.13M | -57.8% |
| 2020 | -$15.29M | -7.8% |
| 2019 | -$14.18M | -6.4% |
| 2018 | -$13.33M | +2.0% |
| 2017 | -$13.60M | -43.9% |
| 2016 | -$9.45M | -7.9% |
| 2015 | -$8.76M | +11.5% |
| 2014 | -$9.89M | +20.2% |
| 2013 | -$12.40M | -41.7% |
| 2012 | -$8.75M | -24.4% |
| 2011 | -$7.04M | -67.8% |
| 2010 | -$4.19M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.85M | +63.6% | +19.7% |
| June 30, 2025 | -$6.04M | +55.9% | +5.7% |
| March 31, 2025 | -$6.40M | +46.7% | +52.0% |
| September 30, 2024 | -$13.33M | -41.6% | +2.7% |
| June 30, 2024 | -$13.70M | -65.2% | -14.2% |
| March 31, 2024 | -$12.00M | -37.9% | -27.5% |
| September 30, 2023 | -$9.41M | -20.4% | -13.5% |
| June 30, 2023 | -$8.29M | -11.5% | +4.7% |
- Cellectar Biosciences, Inc. showed an increase of +55.6% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Cellectar Biosciences, Inc.’s operating income has declined by 448.0% (from -$4.19 million to -$22.98 million).
- The most recent figure is from Cellectar Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: